Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taurine Supplementation for Neurocognitive Symptoms in Long COVID
NCT06721949Phase 3Recruiting
- Sponsor
- University of Alberta
- Start
- Nov 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-COVID-19 condition (PCC) comparing Taurine with Placebo (2 arms). Primary endpoints: Modified Fatigue Impact Scale at 3 months and Trail-Making Tests A & B at 3 months. Started Nov 2025; status: recruiting.
02
Drugs
taurine
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT06721949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06721949.